Innovation Pharma (Formerly known as Cellceutix)
100 Cumming Center, Suite 151-B
Suite A225
Beverly
Massachusetts
01915
United States
Tel: 978-236-8717
Fax: 978-921-6564
Website: http://www.cellceutix.com/
Email: info@cellceutix.com
264 articles about Innovation Pharma (Formerly known as Cellceutix)
-
New Autism Drug Research by Cellceutix on Compound KM-391 Results in Significant Behavioral Changes; Chief Scientific Officer Sees Potential for Company to Emerge as Industry Leader as Pharmas Strive for Revolutionary Autism Treatments
6/14/2010
-
Cellceutix Responds to Public Support by Expediting Autism Studies; Completes Two Required Safety Pharmacology Studies for Its Cancer Compound
6/7/2010
-
Cellceutix CFO Discusses Autism Drug, Kevetrin(TM) and Company Progressions With CEOCFO Interviews and News
6/3/2010
-
Cellceutix Signs Agreements for Kevetrin(TM) Phase 1 Support; Company Continues to Advance Kevetrin Toward Human Studies Targeting Drug Resistant Cancers
5/24/2010
-
Recent Announcements Suggest Cellceutix Is Well Positioned With Autism Compound; Pfizer Inc. And Novartis Corporation Announcements Indicate Interest in Autism by Major Companies
5/12/2010
-
Cellceutix Presents Poster Session at American Association for Cancer Research; Important New Data on Kevetrin(TM) in Resistant Lung Cancer Model Show Dose Response; No Tumor Cell Resistance With Second Cycle
4/21/2010
-
Cellceutixx CEO Appears on 'Stu Taylor on Business': Cancer and Autism Compounds Are Discussed
4/12/2010
-
Cellceutix Announces Positive Results With Autism Compound KM-391, Showing Significant Improvements on Key Parameters in Animal Studies
3/29/2010
-
Cellceutix Signs Agreement for Kevetrin(TM) Formulation With Formatech, Inc.
3/22/2010
-
Cellceutix Abstract Accepted by American Association for Cancer Research
3/15/2010
-
Cellceutix Completes Successful Pre-IND Meeting With FDA for Cancer Drug
2/16/2010
-
Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies With Toxikon Corporation
11/2/2009
-
Cellceutix Release: Attacking Cancer With Specific Anti-Tumor Pathways
10/20/2009
-
Cellceutix Poster Presented At American Association for Cancer Research; Dr. Menon Selected for Expert Panel
10/13/2009
-
Cellceutix Compound Shows Significant Effect On Psoriasis
10/6/2009
-
Cellceutix Meets With One of the World's Largest Pharmaceutical Companies At Partnering Meeting
9/23/2009
-
Cellceutix Announces Acquisition of New Compound With High Blood Pressure Lowering Properties
8/25/2009
-
Cellceutix Signs Agreement with Girindus for Kevetrin(tm) API
8/17/2009
-
Cellceutix's Cancer Drug Shows No Significant Indications of Toxicity
7/22/2009
-
Cellceutix Announces Dr. Samuel Danishefsky Joins Its Scientific Advisory Board
7/15/2009